Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.68 |
| ▸ | HPGD | P15428 | 6/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.68 |
| ▸ | ALB | P02768 | 1/20 | 0.68 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.67 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.67 |
| ▸ | TUBB | P07437 | 1/20 | 0.67 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.67 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.67 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.67 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.67 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.67 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.67 |
| ▸ | TUBB8 | Q3ZCM7 | 1/20 | 0.67 |
| ▸ | TUBA3E | Q6PEY2 | 1/20 | 0.67 |
| ▸ | TUBA1A | Q71U36 | 1/20 | 0.67 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vebufloxacin SCHEMBL29391678 | 1.00 | LMNA (0.82) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Vebufloxacin SCHEMBL11160410 | 0.98 | LMNA (0.79) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11185046 | 0.92 | LMNA (0.85) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11000799 | 0.91 | LMNA (0.83) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10995672 | 0.91 | LMNA (0.83) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10994613 | 0.91 | LMNA (0.87) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11163121 | 0.91 | LMNA (0.76) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL11169414 | 0.90 | LMNA (0.79) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Nadifloxacin SCHEMBL3818938 | 0.90 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 | |
| Levonadifloxacin SCHEMBL36594 | 0.90 | LMNA (1.00) | LMNAKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285572-A1 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC | 2023-09-14 | — | — | US | claimed |
| EP-4188433-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | Sepelo Therapeutics, LLC (US) | 2023-06-07 | — | — | EP | claimed |
| WO-2023028364-A1 | TARGETED COMPOSITIONS AND USES THEROF | SEPELO THERAPEUTICS, LLC (US) | 2023-03-02 | — | — | WO | claimed |
| WO-2022031761-A2 | TARGETED DELIVERY OF THERAPEUTIC AGENTS | SEPELO THERAPEUTICS, LLC (US) | 2022-02-10 | — | — | WO | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | claimed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| EP-3752201-B1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | UNIV FRIEDRICH ALEXANDER ER (DE) | 2023-11-22 | — | — | EP | disclosed |
| US-11786599-B2 | Releasable conjugates | QUIAPEG PHARMACEUTICALS AB (SE) | 2023-10-17 | — | — | US | disclosed |
| EP-0047005-B1 | BENZOXAZINE DERIVATIVES | DAIICHI SEIYAKU CO., LTD. (JP) | 1984-11-14 | — | — | EP | disclosed |
| EP-0101829-A2 | Tricyclic compounds, a process for their production and pharmaceutical compositions containing said compounds | DAIICHI SEIYAKU CO., LTD. (JP) | 1984-03-07 | — | — | EP | disclosed |
| US-4416884-A | ANTIBIOTIC, BACTERICIDE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1983-11-22 | — | — | US | disclosed |
| US-4382892-A | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1983-05-10 | — | — | US | disclosed |
| EP-0047005-A1 | Benzoxazine derivatives | DAIICHI SEIYAKU CO., LTD. (JP) | 1982-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | LMNA 2176/4885KDM4E 3590/4885ALDH1A1 72/4885 |
| US-11786599-B2 | Releasable conjugates | GUSB, ABCB11, UGT2B7 | LMNA 2176/4885KDM4E 3590/4885ALDH1A1 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.